Analysts expect Redhill Biopharma Ltd. (NASDAQ:RDHL) to post earnings per share (EPS) of ($0.76) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Redhill Biopharma’s earnings, with the lowest EPS estimate coming in at ($0.80) and the highest estimate coming in at ($0.71). Redhill Biopharma reported earnings per share of ($0.70) during the same quarter last year, which would suggest a negative year-over-year growth rate of 8.6%. The firm is scheduled to report its next earnings report on Monday, November 13th.

On average, analysts expect that Redhill Biopharma will report full year earnings of ($2.64) per share for the current year, with EPS estimates ranging from ($2.70) to ($2.58). For the next financial year, analysts expect that the firm will post earnings of ($2.28) per share, with EPS estimates ranging from ($2.50) to ($2.05). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that cover Redhill Biopharma.

Redhill Biopharma (NASDAQ:RDHL) last announced its earnings results on Tuesday, July 25th. The biotechnology company reported ($0.60) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by $0.02. The company had revenue of $0.48 million during the quarter, compared to analyst estimates of $0.34 million.

Several analysts have recently commented on the stock. Roth Capital set a $27.00 price objective on shares of Redhill Biopharma and gave the company a “buy” rating in a research report on Monday, July 31st. Zacks Investment Research downgraded shares of Redhill Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, July 29th. HC Wainwright set a $33.00 price target on shares of Redhill Biopharma and gave the company a “buy” rating in a report on Wednesday, July 26th. Finally, FBR & Co reiterated a “buy” rating on shares of Redhill Biopharma in a report on Friday, June 16th.

Redhill Biopharma (RDHL) opened at 8.85 on Tuesday. Redhill Biopharma has a 52 week low of $8.16 and a 52 week high of $15.93. The company’s market cap is $151.89 million. The company’s 50-day moving average price is $8.95 and its 200 day moving average price is $9.52.

Several hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp acquired a new stake in Redhill Biopharma during the first quarter worth $101,000. Family Management Corp purchased a new position in Redhill Biopharma during the first quarter worth approximately $163,000. Penserra Capital Management LLC boosted its position in Redhill Biopharma by 75.0% in the first quarter. Penserra Capital Management LLC now owns 17,843 shares of the biotechnology company’s stock worth $171,000 after buying an additional 7,647 shares in the last quarter. Oppenheimer & Co. Inc. boosted its position in Redhill Biopharma by 36.5% in the first quarter. Oppenheimer & Co. Inc. now owns 23,069 shares of the biotechnology company’s stock worth $221,000 after buying an additional 6,172 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in Redhill Biopharma during the fourth quarter worth approximately $266,000. Hedge funds and other institutional investors own 12.22% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/08/22/0-76-earnings-per-share-expected-for-redhill-biopharma-ltd-rdhl-this-quarter.html.

Redhill Biopharma Company Profile

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Get a free copy of the Zacks research report on Redhill Biopharma (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Redhill Biopharma (NASDAQ:RDHL)

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.